WO2002060486A2 - Controlled release microsphere system for administration of drug to the eye - Google Patents
Controlled release microsphere system for administration of drug to the eye Download PDFInfo
- Publication number
- WO2002060486A2 WO2002060486A2 PCT/CA2002/000086 CA0200086W WO02060486A2 WO 2002060486 A2 WO2002060486 A2 WO 2002060486A2 CA 0200086 W CA0200086 W CA 0200086W WO 02060486 A2 WO02060486 A2 WO 02060486A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- microspheres
- composition
- wall
- chemical
- neutralizing agent
- Prior art date
Links
- 239000004005 microsphere Substances 0.000 title claims abstract description 138
- 229940079593 drug Drugs 0.000 title description 26
- 239000003814 drug Substances 0.000 title description 26
- 238000013270 controlled release Methods 0.000 title 1
- 238000006243 chemical reaction Methods 0.000 claims abstract description 51
- 230000003472 neutralizing effect Effects 0.000 claims abstract description 49
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 45
- 102000029816 Collagenase Human genes 0.000 claims abstract description 21
- 108060005980 Collagenase Proteins 0.000 claims abstract description 21
- 229960002424 collagenase Drugs 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 20
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000000203 mixture Substances 0.000 claims description 75
- 239000008196 pharmacological composition Substances 0.000 claims description 56
- 239000000126 substance Substances 0.000 claims description 50
- 150000001875 compounds Chemical class 0.000 claims description 30
- 102000008186 Collagen Human genes 0.000 claims description 10
- 108010035532 Collagen Proteins 0.000 claims description 10
- 229920001436 collagen Polymers 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 8
- 238000007789 sealing Methods 0.000 claims description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 5
- 229910052791 calcium Inorganic materials 0.000 claims description 5
- 239000011575 calcium Substances 0.000 claims description 5
- 239000002738 chelating agent Substances 0.000 claims description 5
- 230000035484 reaction time Effects 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 2
- 230000000977 initiatory effect Effects 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 abstract description 6
- 210000002159 anterior chamber Anatomy 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 229920000249 biocompatible polymer Polymers 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 239000001263 FEMA 3042 Substances 0.000 description 2
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 229920002258 tannic acid Polymers 0.000 description 2
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 2
- 229940033123 tannic acid Drugs 0.000 description 2
- 235000015523 tannic acid Nutrition 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 238000009775 high-speed stirring Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
- A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/00781—Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment
Definitions
- the present invention concerns a method and apparatus for controlling a chemical reaction caused by the administration of a chemical compound to an organism. More particularly, this invention is concerned with controlling the administration of drugs to the eye, and more particularly to controlling the reaction time of administered drugs to the eye.
- this may translate into a drug being administered at the lowest possible dosage, or it may mean that a drug will be administered for a minimum amount of time.
- Another way is to administer the drug for a specified period of time, and then manually remove the administration device.
- Such a method is disclosed in U.S. Patent No. 5,462,739 (Dan et al.).
- Dan et al. teaches a device and method for pinpoint delivery of pharmacological compositions to the outer hard coat of the eye, and particularly for pinpoint application of collagenase to the limbus for the treatment of glaucoma.
- a specified quantity of collagenase is applied using a device at a specific, pinpoint location on the limbus.
- the collagenase degrades the collagen structures in the limbus, thereby forming a pinpoint hole into the anterior chamber of the eye, releasing aqueous from the anterior chamber, and reducing pressure in the eye.
- Dan et al. teaches that the degradation of the collagen structures by the collagenase occurs preferably only for a specified period of time, after which the administration device is removed manually from the eye and the eye is then flushed with a solution of calcium chelator ethylenediaminetetraacetic acid, hereinafter referred to as calcium chelator EDTA.
- calcium chelator EDTA calcium chelator ethylenediaminetetraacetic acid
- the present invention is directed to microspheres for use in automatically controlling a chemical reaction, and particularly, the administration of a pharmacological composition to the eye, wherein each microsphere comprises a wall that is degradable by the composition, and a neutralizing agent, that neutralizes the composition, stopping the administration of the composition to the eye.
- the thickness and chemical formula of the wall are selected to expose the neutralizing agent to the composition after a selected period of time.
- a system of microspheres each of said microspheres comprising: a compound adapted for altering a chemical reaction caused by the administration of a chemical composition to an organism; and a wall, said wall enclosing said compound, and said wall being degradable by at least one chemical present during said chemical reaction.
- the compound can alter the reaction by stopping the reaction or slowing the reaction, by reaction with one or more of the chemicals present. Further, the compound can react with at least one chemical present to change the nature of the reaction or initiate a second, different reaction.
- the microspheres can also contain one or more additional compounds to creating the desired reaction scheme. For example, one compound would stop the first reaction, as detailed above, and a second compound could then start a second chemical reaction. Further, the invention contemplates the use of embedded, slow release systems. For example, a chemical reaction would be controlled in any of the ways outlined above. For example, the relevant compound or compounds could be encased in a hyaluronic polymer, which are known for controlled, slow release drug systems.
- the invention is directed to an insert that contains microspheres for use with a microcontainer of a pharmacological composition for administration to the eye.
- the insert is removably insertable into the microcontainer.
- the microspheres are the same as those described above, and therefore stop the administration of the composition after a selected period of time, by neutralizing the composition.
- the invention is directed to a method of administering a pharmacological composition to a body to obtain a reaction between the pharmacological composition and the body, and controlling the reaction time, the method comprising:
- microspheres comprising a wall that is degraded by at least one chemical present during the reaction of the pharmacological composition with the body and, contained by the wall, a neutralizing agent for neutralizing the pharmacological composition;
- the invention is directed to a system of microspheres, including first and second microspheres.
- Each of the first microspheres includes a chemical composition for administering to an organism and for causing a chemical reaction within the organism.
- Each of the first microspheres includes a wall that encloses the chemical composition, and is permeable to the chemical composition at a selected rate.
- Each of the second microspheres includes a compound adapted for altering a chemical reaction caused by the administration of the chemical composition to the organism.
- Each of the second microspheres includes a wall that encloses the compound, and is degradable by at least one chemical present during the chemical reaction.
- the invention is directed to a system for administering a chemical composition to a target site in an organism, including a chemical composition for administration to the target site, a system of microspheres and a housing.
- Each of the microspheres includes a compound adapted for altering a chemical reaction caused by the administration of the chemical composition to the organism.
- Each of the microspheres includes a wall that encloses the compound, and is degradable by at least one chemical present during the chemical reaction.
- the housing encloses the chemical composition and the microspheres together in a cavity. The housing is permeable to the chemical composition at a selected rate.
- Figure 1 is a view of a system of microspheres in accordance with a first embodiment of the present invention, with a sectional side view of a single microsphere;
- Figure 2 is a sectional side elevation view of a known application device for applying a pharmacological composition to the eye;
- Figure 3 is an isometric view of a device in accordance with the present invention, for use with the application device of Figure 2;
- Figure 4 is a view of a system of microspheres in accordance with an alternative embodiment of the present invention, with a sectional side views of microsphere of each different type;
- Figure 5 is a perspective view of a system for delivering a composition to a target site in an organism in accordance with another alternative embodiment of the present invention.
- Figure 6 is a sectional side view of the device shown in Figure 5, taken along section line 6-6.
- FIG. 1 illustrates a system of microspheres 10 made in accordance with a first preferred embodiment of the present invention and which will be used for the purposes of describing the operational aspects of the invention.
- the present invention provides for the addition of a quantity of the microspheres 10, so that the added microspheres 10 serve to stop the chemical reaction from continuing after a predetermined period of time.
- a quantity of microspheres 10 can be included in the composition, such that, after a specified period of time, the microspheres 10 release a neutralizing agent to stop the further administration of the composition to the eye, the neutralizing agent neutralizing the active drug or drugs in the composition.
- each microsphere 10 comprises a generally spherical wall 12, which encloses a generally spherical cavity 14, which holds a neutralizing agent 16.
- Wall 12 is made from a material that is selected to be degradable by the composition being administered to the eye.
- wall 12 can be made from cross-linked collagen, or collagen gelatin.
- the thickness "t" and the chemical formula of wall 12 are selected based on the length of time desired for the chemical reaction to occur. If it is desired for the active drug to act on the eye for a relatively long period of time, a relatively thick wall 12 and/or a relatively slow-to-degrade wall material may be selected, so that it takes longer for wall 12 to be degraded. Conversely, if a short period of time is desired, a relatively thin wall 12 and/or relatively chemically active wall material may be selected, so that it takes less time for wall 12 to be degraded.
- Diameter 'd' of microspheres 10 is selected based on the specific application, and may depend on the wall thickness 't'. If a specific quantity of neutralizing agent 16 is required per microsphere, then the volume of cavity 14 is determined by the quantity of neutralizing agent required, and therefore the diameter 'd' of the microsphere 10 depends on the wall thickness selected for the specific application.
- Neutralizing agent 16 is selected to react with and neutralizes or otherwise stops the pharmacological composition, preventing further administration of the composition on the eye.
- neutralizing agent 16 is preferably a solution of calcium chelator EDTA.
- a sufficient quantity of neutralizing agent 16 must be contained within microspheres 10, such that all of the active drug or drugs in the pharmacological composition are neutralized, and that no residual amount of active drug in the composition continues to act on the eye.
- An advantage of using microspheres is that the neutralizing agent is present, in numerous small amounts, uniformly distributed throughout the composition, so that no mixing is required.
- Both wall 12 and neutralizing agent 16 may also be designed to meet other criteria.
- wall 12 and neutralizing agent 16 must also be selected to be biologically compatible with the eye.
- both wall 12 and neutralizing agent 16 are biodegradable and/or resorbable in the body once their function has been performed.
- neutralizing agent 14 is preferably selected to be pH compatible with the eye, and would therefore have a pH of approximately 7.4.
- Fig. 2 shows an application device 20, as disclosed in U. S. Patent No. 5,462,739 (Dan et al.), for the administering of a pharmacological composition to a pinpoint location on the hard outer coat of the eye. The contents of U.S.
- Patent 5,462,739 are hereby incorporated by reference.
- a device such as a syringe, or one of the devices disclosed by Dan et al. Is used to aid in administering a drug or pharmacological composition to the eye.
- devices such as device 20
- the pharmacological composition be stored in device 20 for an unspecified period of time, perhaps several hours, before the drug is administered.
- microspheres 10 be employed as described above to stop the administration of the drug to the eye, it will often be desirable that microspheres 10 not be in contact with the composition until the composition is administered to the eye, so that the release of neutralizing agent 16 only occurs after the composition has acted on the eye for the desired period of time.
- Device 20 includes an administering piece 22 and an introducer 24.
- Administering piece 22 is generally disk shaped and includes an integrally formed microcontainer 26, which holds the drug to be administered.
- Introducer 24 holds administering piece 22 and is used to help position administering piece 22 on the eye.
- Introducer 24 includes a shield surface 28 which serves to seal microcontainer 26 until the administering piece 22 is positioned on the eye.
- a chamber 30 is formed when administering piece 22 is in place on introducer 24. Chamber 30 is used to contain adhesive, which will affix administering piece 22 to the eye.
- administering piece 22 is oriented so that microcontainer 26 is upright, and a quantity of a pharmacological composition is placed inside microcontainer 26.
- a quantity of adhesive, such as medical glue is then placed on surface 32 of piece 22, and introducer 24 is placed on top of piece 22, so that shield surface 28 seals microcontainer 26, and so that piece 22 is well seated on seating portion 34.
- the assembly is then inverted so that microcontainer 26 is open-face-down, as shown in Figure 3.
- Device 20 is then used to administer the pharmacological composition using the following method.
- Device 20 is held in place adjacent the point to be treated, and the introducer 24 is removed while pressure is applied to depression 36 on dorsal surface 38, thereby removing introducer 24 from under piece 22.
- Piece 22 at this point is in position on the surface of the eye, so that microcontainer 26 is open-face-down at the point on the limbus to be treated, and the adhesive is in contact with the surface of the body, holding piece 22 in place.
- the pharmacological composition in microcontainer 26 acts on the pinpoint location of the limbus, covered by microcontainer 26.
- the pharmacological composition may contain collagenase which breaks down the collagen structure in the limbus.
- the collagenase will form a cone shaped hole into the anterior chamber of the eye, releasing aqueous, and thereby reducing the pressure in the eye.
- FIG 3 shows an insert device 40 in accordance with the present invention, for use with the application device shown in Figure 2. Since it is important to keep the microspheres 10 separate from the pharmacological composition until it is desired that they are exposed to each other, insert 40 may be employed to seal microspheres 10 from the composition, within microcontainer 26.
- Insert 40 comprises a microcontainer 42 for containing microspheres 10, a locking means 44, a sealing surface 46, a push-down surface 47 and a removal tab 48. Insert 40 can be removably inserted into microcontainer 26, such that microspheres 10 are stored in microcontainer 42 of insert 40, and the pharmacological composition is stored in the remaining volume of microcontainer 26. In order to accomplish this, microspheres 10 must be introduced into microcontainer 42; then insert 40 is to be inserted, into microcontainer 26, with sealing surface 46 in contact with the bottom of microcontainer 26; and then the pharmacological composition is to be introduced into the remaining volume of microcontainer 26.
- locking means 44 maintains device 40 in a constant upright orientation when device 40 is in place in microcontainer 26, in order to help seal the contents of microcontainer 42 from the contents of the microcontainer 26. Because microcontainer 26 is disclosed by Dan et al. to be generally in the shape of a right cylinder in a particular embodiment, locking means 44 may comprise a partial right cylindrical form such that, circumferentially, the locking means 44 includes more than a 180° of a right cylinder, and therefore has a supra-semi-cylindrical contour face.
- locking means 44 may be any form or shape that serves to maintain device 40 in a specific orientation when inserted into microcontainer 26.
- sealing surface 46 is smooth and contacts the bottom of microcontainer 26 uniformly, so as to inhibit leakage into or out of microcontainer 42.
- Push- down surface 47 simultaneously contacts shield 28, thereby helping to clamp device 40 in position in microcontainer 26.
- Device 40 must be sized such that, when device 40 is inserted into microcontainer 26, shield 28 can still contact and seal microcontainer 26.
- Device 40 can be removed from microcontainer 26 by means of removal tab 48. Just before the application of administering piece 22 to the eye, device 20 is inverted and piece 22 is temporarily removed from introducer 24.
- Insert 40 is then removed from microcontainer 26 so that microspheres 10 remain in microcontainer 26, and mix with the pharmacological composition in microcontainer 26.
- Piece 22 is then re- placed onto introducer 24, and the assembly is inverted again for positioning on the limbus of the eye.
- the microspheres can be stored separately, and when required, a suitable quantity of them can be injected into microcontainer 26, so as not to use insert 40.
- microspheres 10 of the present invention For the treatment of glaucoma, in order to use microspheres 10 of the present invention to automatically stop the administering of collagenase to the limbus of the eye using a device and method as disclosed by Dan et al, it is preferable to determine the length of time required for the collagenase to penetrate into the anterior chamber of the eye and release aqueous. In order to determine the length of time required, the scleral thickness may be measured, by means of an ultrasonic device, as is known in the art. From the thickness of the sclera, the reaction time can then be calculated, and microspheres 10 with the appropriate wall thickness 't' or the appropriate wall composition can be selected to be inserted into the collagenase composition.
- microspheres 10 may further include a coating of albumin, as albumin is non-antigenic, and biodegradable.
- Microspheres 10 with collagen walls 12 and containing EDTA as the neutralizing agent 16 may be manufactured by the following method.
- An aqueous solution of collagen and EDTA is first formed.
- the pH of the solution may be controlled, preferably by adding an alpha-hydroxy acid.
- the addition of the acid to the solution aids in the stability of the microspheres that are formed by this method.
- the aqueous solution is then added to an immiscible liquid or oil phase, and the resulting droplets of collagen and EDTA are then dispersed by high speed stirring, forming a suspension. Stabilization of the suspended droplets, to form microspheres 10 is brought about by heating the suspension.
- chemical cross-linking may be employed to stabilize the droplets and form microspheres 10, using a cross-linking agent, such as glutaraldehyde.
- stabilization of the suspension of droplets may be made to occur by subjecting the droplets of ultraviolet radiation.
- ultraviolet radiation when using ultraviolet radiation, however, the liquid in which the droplets are suspended must be substantially ultraviolet transparent.
- ultraviolet radiation may be used to cause the polymerization of certain chemical components of microspheres 10 in the suspension, in the aqueous solution, or in the stabilized microsphere itself.
- Proteins used in the production of microspheres 10 may be modified proteins. Proteins may be modified at any stage, in the aqueous solution, in the suspension, or in the stabilized microsphere 10.
- Tannic acid may be used in the cross-linking step of manufacture. If tannic acid is used in this step, the resulting anti-enzyme activity caused by the microspheres is affected and must be considered for the specific application. A number of methods may be used to separate microspheres
- an insert such as insert 40 may be made from a number of materials, such as titanium or a biocompatible polymer
- an insert may be made from a material that is itself selected to degrade as a result of the composition in microcontainer 26, similarly to the walls 12 of the microspheres 10 themselves.
- Such an insert would therefore not require a removal tab 48, and furthermore, the insert could be completely sealed, thus facilitating the insert's placement in microcontainer 26.
- such an insert may be configured in size and shape for use with other application devices for introducing pharmacological compositions to other parts of the human body, or to other organisms. Because such an insert would be degraded by the pharmacological composition, the insert would preferably be placed in microcontainer 26 immediately before the composition is administered.
- Microspheres 10 may be made to be pH-sensitive, such that they will release neutralizing agent 16 upon exposure to an environment greater than, or alternatively, less than a specified pH.
- the microspheres can be made to release neutralizing agent 16 upon exposure to a pH of 7.4 or greater.
- the microspheres can have a wall that is stable at one pH, but when exposed to a solution having a pH of 7.4, may degrade at a known rate until the neutralizing agent within the microspheres is released.
- These microspheres 10, added to a collagenase composition and administered to the limbus of the eye, would be exposed to the aqueous, once the collagenase has penetrated into the anterior chamber of the eye.
- microspheres 10 pH-sensitive can be used as an alternative method of making microspheres 10 release neutralizing agent 16. If microspheres 10 are made to be pH-sensitive, they do not require walls 12 to be made from a substance that is degradable by a component of the pharmacological composition. In this way, microspheres 10 are adapted to release neutralizing agent 16 automatically at the correct moment, (ie. when they are exposed to aqueous from the eye, indicating therefore that the collagenase has penetrated into the anterior chamber), regardless of the exact length of time required for the penetration to occur. Alternatively, microspheres 10 may be made to be both pH-sensitive and to have walls 12 that are degradable by a component of the pharmacological composition. PH- sensitive or insensitive microspheres may be made by selecting polyglycerol esters.
- Microspheres 10 of different levels of pH-sensitivity, of different chemical components, containing different neutralizing agents 16, and of different diameters and wall thicknesses may be employed in a single pharmacological composition, in order to selectively neutralize specific components of the composition after different periods of time.
- the anionicity or cationicity of the microspheres can influence the body's response to them, however a pH of above 5 is optimal to prevent neutralization of charge and resulting in aggregation.
- microspheres have been shown to be used for inhibiting the prescription of a composition on the eye, they can alternatively be used to inhibit the administering of pharmacological compositions to other parts of the human or animal body, or furthermore, to other organisms.
- System 50 can be used to release a pharmacological composition 54 into a target site in the body of a human or other organism, on a time-release basis, and then stop the reaction between the composition at the site after a selected period of time.
- the first microspheres 52 have a generally spherical wall 56, surrounding a generally spherical cavity 58. Inside the cavity 56 is the pharmacological composition 54.
- the first microspheres 52 may be made by any suitable means.
- the first microspheres 52 may be made as disclosed in US Patent No. 6,228,423 (Sokoll et al.), which is hereby incorporated by reference.
- the first microspheres 52 can provide a wall defining a cavity encapsulating the compound or the microspheres can be essentially homogenous, i.e. without a distinct cavity and with the compound then distributed through the wall.
- the wall 56 may be made from a biocompatible polymer, which may also be biodegradable.
- the wall 56 may have any suitable selected permeability to the composition 54, so that the composition 54 is released at the target site at a selected rate, and is thus, time-released.
- the wall 56 may be selected to biodegrade after the release of all of the composition 54, so that any amount of the composition 54 can be provided within the cavity 56 for release in a time-controlled manner in the composition 50, before the microspheres 10 stop the reaction. After a selected period of time, or alternatively at a selected point in the reaction of microspheres 52 at the target site, i.e.
- microspheres 10 break down and release the neutralizing agent 16 to stop the reaction.
- the breakdown of the microspheres 10 may be as a result of the composition 54.
- microspheres 10 may be biodegradable and may therefore break down from reaction with body chemicals present at the target site.
- the neutralizing agent 16 is then selected to neutralize any of composition 54 that is present outside of microspheres 52.
- neutralizing agent 16 may be selected to also initiate or to escalate and complete the breakdown of walls 56 of microspheres 52, so that any remaining composition 54 present inside microspheres 52 is also released and thus neutralized relatively quickly.
- the agent 16 can be a two component system; one component would be a neutralizing agent for the composition 54 and the other component could be a solvent for the walls 56 or other agent that breaks down the walls 56.
- microspheres could be present to initiate a second reaction with a desired part of the body or organism, once the first reaction described above has been terminated.
- additional compounds or compositions can be provided within one or both of the first and second microspheres 16, 54.
- one or more other microspheres can be provided, each additional group of microspheres corresponding to one of the microspheres 16, 52 in basic structure.
- FIGS 5 and 6 show a system 60 including a pharmacological composition 62, microspheres 10 and an implantable device 64 for delivering composition 62 in a time- controlled manner to a specific portion of the body of an organism, which avoids the need to provide two different types of microspheres.
- Device 64 may be the device described in US Patent No.
- the device 64 may include a polymer housing 66, which encloses a cavity 68.
- the pharmacological composition 62 and the microspheres 10 are stored in the cavity 68.
- the housing 66 may be made from a suitable biocompatible polymer that has a selected permeablility to composition 62. Housing 66 may be non-biodegradable.
- Housing 66 may be positioned at the target site by any suitable means.
- housing 66 may include a peripheral flange 70 in which is embedded a support ring 72.
- the support ring 72 may be made from a suitable tear-resistant material, such as a biocompatible metal.
- the device 64 may then be surgically inserted into or attached at any suitable point in an organism, for example, in the vitreous of the eye.
- the device 64 may be sutured at the selected target site by routing the suture through the flange 70 inside the support ring 72. Care should be taken to ensure that the suture does not puncture the cavity 68 so that composition 62 is not inadvertently released at an uncontrolled rate.
- the device 64 may then release composition 62 in a time-controlled manner for a selected period of time.
- the housing 66 may be made to be permeable to chemicals (or at least one chemical) in the body that are present at the target site during reaction with the composition, so that these chemicals enter the cavity 68.
- the microspheres 10 are made to degrade in the presence of these chemicals, so that after a selected period of time, the microspheres 10 break down and neutralize any remaining amount of composition 62 in the cavity 68.
- the microspheres 10 can be caused to break down by some other chemical present during the reaction, for example, a reaction product, but this presents the problem of how this chemical is generated and/or becomes present during the reaction.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002229434A AU2002229434A1 (en) | 2001-01-29 | 2002-01-29 | Controlled release microsphere system for administration of drug to the eye |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26429001P | 2001-01-29 | 2001-01-29 | |
US60/264,290 | 2001-01-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002060486A2 true WO2002060486A2 (en) | 2002-08-08 |
WO2002060486A3 WO2002060486A3 (en) | 2003-01-09 |
Family
ID=23005380
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2002/000086 WO2002060486A2 (en) | 2001-01-29 | 2002-01-29 | Controlled release microsphere system for administration of drug to the eye |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2002229434A1 (en) |
WO (1) | WO2002060486A2 (en) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4276284A (en) * | 1971-07-26 | 1981-06-30 | Brown Stuart I | Prevention of collagenase induced disease by treatment with collagenase inhibitors |
GB2237510A (en) * | 1989-11-04 | 1991-05-08 | Danbiosyst Uk | Small particle drug compositions for nasal administration |
DE4038887A1 (en) * | 1990-12-06 | 1992-07-02 | Lohmann Therapie Syst Lts | METHOD FOR THE PRODUCTION OF COLLAGEN PARTICLES AND THEIR USE AS AN ACTIVE SUBSTANCE |
US5185152A (en) * | 1990-01-10 | 1993-02-09 | Peyman Gholam A | Method and apparatus for controlled release drug delivery to the cornea and anterior chamber of the eye |
WO1994010980A1 (en) * | 1992-11-16 | 1994-05-26 | Corporation Of Mercer University | Compositions using microencapsulated neutralizing antibodies |
US5462739A (en) * | 1991-11-21 | 1995-10-31 | Yeda Research And Development Co., Ltd. | Microdelivery device and method for enhanced drug administration to the eye |
WO1998028357A1 (en) * | 1996-12-20 | 1998-07-02 | Connaught Laboratories Limited | Biodegradable targetable microparticle delivery system |
US5965152A (en) * | 1995-04-18 | 1999-10-12 | Galin; Miles A. | Controlled release of miotic and mydriatic drugs in the anterior chamber |
US6001386A (en) * | 1995-09-27 | 1999-12-14 | University Of Kentucky Research Foundation | Implantable controlled release device to deliver drugs directly to an internal portion of the body |
-
2002
- 2002-01-29 AU AU2002229434A patent/AU2002229434A1/en not_active Abandoned
- 2002-01-29 WO PCT/CA2002/000086 patent/WO2002060486A2/en not_active Application Discontinuation
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4276284A (en) * | 1971-07-26 | 1981-06-30 | Brown Stuart I | Prevention of collagenase induced disease by treatment with collagenase inhibitors |
GB2237510A (en) * | 1989-11-04 | 1991-05-08 | Danbiosyst Uk | Small particle drug compositions for nasal administration |
US5185152A (en) * | 1990-01-10 | 1993-02-09 | Peyman Gholam A | Method and apparatus for controlled release drug delivery to the cornea and anterior chamber of the eye |
DE4038887A1 (en) * | 1990-12-06 | 1992-07-02 | Lohmann Therapie Syst Lts | METHOD FOR THE PRODUCTION OF COLLAGEN PARTICLES AND THEIR USE AS AN ACTIVE SUBSTANCE |
US5462739A (en) * | 1991-11-21 | 1995-10-31 | Yeda Research And Development Co., Ltd. | Microdelivery device and method for enhanced drug administration to the eye |
WO1994010980A1 (en) * | 1992-11-16 | 1994-05-26 | Corporation Of Mercer University | Compositions using microencapsulated neutralizing antibodies |
US5965152A (en) * | 1995-04-18 | 1999-10-12 | Galin; Miles A. | Controlled release of miotic and mydriatic drugs in the anterior chamber |
US6001386A (en) * | 1995-09-27 | 1999-12-14 | University Of Kentucky Research Foundation | Implantable controlled release device to deliver drugs directly to an internal portion of the body |
WO1998028357A1 (en) * | 1996-12-20 | 1998-07-02 | Connaught Laboratories Limited | Biodegradable targetable microparticle delivery system |
Also Published As
Publication number | Publication date |
---|---|
AU2002229434A1 (en) | 2002-08-12 |
WO2002060486A3 (en) | 2003-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200230297A1 (en) | Drug Eluting Implant | |
US5505713A (en) | Indwelling catheter with stable enzyme coating | |
US7090888B2 (en) | Sustained release ophthalmological device and method of making and using the same | |
US4959054A (en) | Pharmaceutically protected percutaneous devices | |
US20050245905A1 (en) | Local drug-delivery system | |
US6776792B1 (en) | Coated endovascular stent | |
US20120238994A1 (en) | Two-piece injectable drug delivery device with heat-cured seal | |
Heller | Controlled release of biologically active compounds from bioerodible polymers | |
CN101052435B (en) | Treatment medium delivery device | |
JP5687276B2 (en) | Pulsed release of drug from punctal plug | |
JP4599498B2 (en) | Non-polymer persistent dissociation delivery system | |
US8563082B2 (en) | Method for producing a cross-linked substance, especially in the form of a microcapsule or layer | |
EP0245535A1 (en) | Ultrasonically modulated polymeric devices for delivering compositions | |
JP2011178782A (en) | Manufacture of long-term drug delivery device with polyurethane-based polymer | |
JP2004524866A (en) | Intraocular drug delivery device | |
EP0281482A1 (en) | Polymer blends for selective biodegradability | |
JP2009254864A (en) | Implantable and sealable device for unidirectional delivery of therapeutic agent to tissue | |
KR20080073328A (en) | Controlled drug release composition and drug releasing medical device | |
US20050129732A1 (en) | Biodegradable, antibiotic, controlled release tape | |
JP2021511124A (en) | Implantable microneedles and their manufacturing methods | |
Graham et al. | Polymeric inserts and implants for the controlled release of drugs | |
US20090105811A1 (en) | Intravascular Devices for Cell-Based Therapies | |
GB2227176A (en) | Textured micro implants | |
KR102004014B1 (en) | A drug delivery system | |
EP1973507B1 (en) | Intraocular drug dispenser |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase in: |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |